<DOC>
	<DOCNO>NCT02856438</DOCNO>
	<brief_summary>The objective expand access program provide treatment elotuzumab combination lenalidomide dexamethasone patient relapse refractory multiple myeloma Japanese site license physician determine clinical need .</brief_summary>
	<brief_title>Early Patient Access Treatment Use Protocol CA204-220</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Men woman 20 year older Active , relapse refractory multiple myeloma International Myeloma Working Group ( IMWG ) criterion assess treat physician receive least 1 prior line multiple myeloma therapy . Progression recent line therapy Prior lenalidomide exposure permit fulfill follow : 1 . Were refractory prior lenalidomide , define progression receive lenalidomide ( induction dose ) within 60 day last dose lenalidomide . Patients progress lenalidomide maintenance dose eligible enrollment . 2 . Patient discontinue lenalidomide due Grade ≥ 3 related AE . All Adverse Events prior chemotherapy , surgery , radiotherapy resolve NCI CTCAE ( v. 3.0 ) Grade ≤ 2 Significant cardiac disease determine treat physician include cardiac amyloidosis Known HIV infection active hepatitis A , B , C Any medical condition , attend physician 's opinion , would impose excessive risk patient . Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>